CoQ10 in Patients with Nonalcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease is the most common cause of chronic liver injury.  After 4 weeks of CoQ10 supplementation, waist circumference and serum AST concentrations were significantly decreased as compared to the placebo-treated group.  The study showed a potential for CoQ10 therapy in improving serveral anthropometric and biochemical variables in non-alcoholic fatty liver disease.  Longer studies with higher doses of CoQ10 are required to further evaluate this potential benefit.

Here is the link to the entire article:

Oral Coenzyme Q10 Supplementation Improves Various Anthropometric and Biochemical Variables in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

God bless you and to your good health!

Joyce Gibb MS, CRNP

Ask The Pharmacist Group, LLC

[product id="2421"][product id="2423"]

Back to blog